期刊档案 · Medicine-Pharmacology (medical)
Therapeutic Advances in Vaccines and Immunotherapy
ISSN 2515-1355 · eISSN 2515-1363 · SAGE Publishing · United Kingdom
Therapeutic Advances in Vaccines and Immunotherapy 钻石开放获取（无 APC），免版面费，近 24 个月 34 篇文章投稿到接收中位 132 天，官网公布录用率 30%，2025 年发文 22 篇，Scopus 收录。
研究范围
研究范围与定位
Therapeutic Advances in Vaccines and Immunotherapy 由 SAGE Publishing 出版。按 OpenAlex 近年发文统计，该刊主要发表 Vaccine Coverage and Hesitancy、SARS-CoV-2 and COVID-19 Research、Immunotherapy and Immune Responses 等主题的论文，这 3 个主题约占 43.1%。（根据 OpenAlex 主题统计与中科院分区数据生成）
Therapeutic Advances in Vaccines and Immunotherapy delivers the highest quality peer-reviewed open access articles, reviews, and scholarly comment relating to advances in the fields of vaccinology and immunotherapy. The journal covers all research relevant to the prospects of recovering a natural, or enhancing an induced, immune response, reporting on advances in vaccination (both prophylactic and therapeutic) as well as an ever-growing repertoire of other immunotherapeutic interventions.Therapeutic Advances in Vaccines and Immunotherapy covers themes including but not limited to:Immunotherapy for CancerVaccine DevelopmentPersonalised ImmunotherapyVaccine Adjuvants and FormulationImmunotherapeutic TargetsImmunotherapy and Autoimmune DiseasesVaccine Delivery SystemsImmune Response MonitoringVaccination Strategies in low-resource settingsVaccine strategies in emerging Infectious DiseasesEthical and Regulatory ConsiderationsGlobal Health policies on Access to VaccinesVaccine Hesitancy and CommunicationImmune Memory and Long-Term ProtectionVaccine Safety and Adverse EventsThe journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, post-marketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Vaccines and Immunotherapy conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of acceptance.
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Medicine-Pharmacology (medical)
主编 Zachary Hartman出版商官网
编委会国家分布：未见中国大陆编委；主要国家 美国 17、印度 7、英国 6、意大利 3、澳大利亚 3（共 52 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Vaccine Coverage and HesitancySocial Sciences21.1%
- SARS-CoV-2 and COVID-19 ResearchMedicine14.5%
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.6%
- Intramuscular injections and effectsMedicine5.9%
- Cancer Immunotherapy and BiomarkersMedicine4.6%
- COVID-19 Clinical Research StudiesMedicine4.3%
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics4.3%
- Cervical Cancer and HPV ResearchMedicine3.6%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
CiteScore 分区（Scopus，2026 年 6 月版）
| 学科 | 分区 | 排名 | 百分位 |
|---|---|---|---|
| Pharmacology (medical) | Q1 | 64/278 | 77% |
| Oncology | Q2 | 109/428 | 74% |
| Immunology and Allergy | Q2 | 86/234 | 63% |
| Drug Discovery | Q2 | 60/161 | 63% |
| Immunology | Q2 | 94/243 | 61% |
Scopus 按 CiteScore 在每个学科内为期刊排名，百分位 75 及以上为 Q1，每 25 为一档；与中科院分区是不同体系。LetPub
数据库收录
ScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- CiteScore 2026-06
- 6LetPub ·
- SJR 2026-06
- 0.83LetPub ·
- SNIP 2026-06
- 0.95LetPub ·
- h-index
- 23OpenAlex ·
- i10-index
- 49OpenAlex ·
- 两年平均被引
- 5.18OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 142 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 8 | 8 | 329 |
| 2025 | 22 | 22 | 423 |
| 2024 | 27 | 27 | 344 |
| 2023 | 18 | 18 | 289 |
| 2022 | 17 | 17 | 239 |
| 2021 | 14 | 14 | 175 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
132 天投稿到接收中位数 · P25–P75 90 天 – 191 天
- 接收到上线
- 中位数 28 天（34 篇）
- 投稿到上线
- 中位数 163 天
- 样本
- 34 篇有投稿与接收日期的文章（窗口内共 36 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 8 WeeksLetPub ·
- 录用率（出版商公布）
- 30%出版商官网 ·
- 投稿到首次决定
- 12 天出版商官网 ·
- 接收到发表
- 29 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 8 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
钻石开放获取（无 APC）DOAJ
所有文章开放获取，且不向作者收取文章处理费。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | 无文章处理费 | 无 | CC BY、CC BY-NC | |
| LetPub | 无文章处理费 | 无 | — | |
| 出版商官网 | USD 2,250 / USD 5,500 | — | — |
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点1 项，摘自作者指南
- 参考文献格式
- Vancouver 格式
接收的文章类型9 种
- original articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- original articlesOriginal Articles. The Editors will consider clinical interventional and observational studies with clearly stated aims, well-reported methodology (including ma…未说明篇幅
- original research articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- perspectiveView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- review articleView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
- review articlesReview Articles. These manuscripts are usually commissioned by the Editors but unsolicited reviews will be considered.未说明篇幅
- scoping reviewsScoping Reviews – These reviews assess the scope of available literature on a topic through comprehensive synthesis.未说明篇幅
- systematic reviewView our Special Collections currently accepting submissions. Please visit the Sage Journal Author Gateway for guidance on producing visual and/or video abstrac…未说明篇幅
官网政策摘录作者资格、数据可用性、出版伦理、开放获取、同行评审、查重、预印本、试验注册 / 报告规范
- 作者资格 Author contributions
作者需在提交过程中列出每位作者的具体贡献，并在稿件中致谢部分之后加入“作者贡献”标题，该信息将在校样阶段显示。 模型中文摘要
You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage.
原文 ↗出版商官网 ·- 数据可用性 Data availability
期刊鼓励作者在符合伦理和法律要求的前提下，将研究数据存入相关公共数据仓库、提供链接数据的数据可用性声明（如无法共享需说明原因）并在研究中引用该数据。 模型中文摘要
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
原文 ↗出版商官网 ·- 出版伦理 Ethical considerations
涉及人类参与者、人类数据或人体组织的研究必须声明相关伦理委员会或机构审查委员会批准或豁免批准，并提供委员会全称、所属机构及批准号；若无需伦理批准也须明确说明。 模型中文摘要
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
原文 ↗出版商官网 ·- 开放获取 Publishing fees and open access
该刊为开放获取期刊，接受文章在出版后立即免费在线发布并采用知识共享许可，文章处理费（APC）为2250美元，在同行评审接受后、出版前支付，可能需缴税。 模型中文摘要
Therapeutic Advances in Vaccines and Immunotherapy is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. The article processing charge (APC) is $2,250. More details on APCs for specific article types can be found in the Article Type section below…
原文 ↗出版商官网 ·- 同行评审 Peer review policy
该刊采用单匿名同行评审，稿件先经初步评估，不符合要求会被退回修改，超出范围或不合适的稿件可能未经同行评审即被直接拒稿。 模型中文摘要
The following summary describes the peer review process for this journal: Identity transparency:Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk reject…
原文 ↗出版商官网 ·- 查重 Plagiarism
期刊和Sage非常重视版权侵权、抄袭及其他出版违规问题，作者应阅读Sage关于抄袭的完整政策及可能采取的措施。 模型中文摘要
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
原文 ↗出版商官网 ·- 预印本 Preprints
期刊接受曾在预印本服务器发布过的稿件，提交时需在指定字段填写预印本DOI，并建议告知编辑部，但在同行评审期间不应在预印本服务器发布更新版本。 模型中文摘要
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
原文 ↗出版商官网 ·- 试验注册 / 报告规范 Clinical trial registration
临床试验须在纳入首例参与者之前或当时在WHO认可的公共试验注册机构注册，并在摘要末尾注明注册机构名称、网址及注册号。 模型中文摘要
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- SAGE Publishing
- 出版国家或地区
- United Kingdom
- 出版语言
- English
- ISSN
- 2515-1355
- 电子版 ISSN
- 2515-1363
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 Therapeutic Advances in Vaccines and Immunotherapy 的常见问题
Therapeutic Advances in Vaccines and Immunotherapy 的审稿周期多长？
按 2024年11月至2026年11月（近 24 个月）34 篇已发表文章登记的日期，投稿到接收的中位数为 132 天（四分位 90–191 天）；投稿社区反馈的平均审稿速度为约 8 周；期刊官网公布的录用率为 30%。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Therapeutic Advances in Vaccines and Immunotherapy 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 52 位编委中，没有中国大陆学者；人数最多的国家是 美国（17 位）、印度（7 位）、英国（6 位）。统计按编委会页面列出的机构国家计，仅供参考。
Therapeutic Advances in Vaccines and Immunotherapy 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Therapeutic Advances in Vaccines and Immunotherapy 被 Scopus、DOAJ 收录。
Therapeutic Advances in Vaccines and Immunotherapy 是开放获取期刊吗？版面费多少？
Therapeutic Advances in Vaccines and Immunotherapy 为钻石开放获取（无 APC）。不收取文章处理费。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。